Acute Myocardial Infarction and Renal Dysfunction: A High-Risk Combination

By R. Wright, G. Reeder, C. Herzog, R. Albright, B. Williams, David Dvorak, W. Miller, J. Murphy, S. Kopecky, Allan S. Jaffe. Annals of Internal Medicine, 2002

608 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Nephrology

View Paper: https://www.semanticscholar.org/paper/2abb43e155b610fa8314685bef65d916c7d46eef

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. J. Griffith
2. Hani Jneid
3. Allan S. Jaffe
4. A. Levey
5. H. Tighiouart

In Nephrology

1. A. Levey
2. Josef Coresh

Citations in the corpus

• Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. (2004, background): “Furthermore, patients with kidney disease likely receive less aggressive therapy for risk-factor modification (7,8,37).”
• Cardiorenal syndrome. (2008, neutral): “This “therapeutic nihilism” (120) is based on the concern of worsening kidney function (121,122) and leads to treating (cid”
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “In patients referred for CABG, short-acting intravenous GP IIb/IIIa inhibitors (eptifibatide or tirofiban) should be discontinued for at least 2 to 4 hours before surgery (236, 237) and abciximab for at least 12 hours before to limit blood loss and transfusion (238).”